In Budd–Chiari syndrome, elevated CA125 correlates with liver damage, ascites volume, Rotterdam score, recurrence risk, and overall prognosis, prompting Cheng et al. to advocate for dynamic monitoring of CA125 at admission, discharge, and follow-up [24]. The gene discussed is MUC16; the disease is Ascites.